Forkhead box protein J3 (FOXJ3) (FOXJ3)

Forkhead box protein J3 (FOXJ3) is a member of the forkhead family of transcription factors, characterized by a conserved DNA-binding domain known as the forkhead box. It serves as a key transcriptional regulator involved in several critical biological processes, including mitochondrial biogenesis, muscle development, and spermatogenesis [UniProt: Q9UPW0]. FOXJ3 exerts its effects by modulating the expression of downstream targets such as PGC-1alpha and Mef2c, which are essential for metabolic homeostasis and cellular differentiation [PubMed: 24508279]. In human pathology, FOXJ3 has been implicated in various cancers, where it often acts as a tumor suppressor; its reduced expression is frequently linked to tumor progression and poor prognosis in colorectal and breast cancers [PubMed: 28656234]. Although FOXJ3 mRNA and protein are recognized as significant biological nodes, there are currently no FDA-approved drugs or clinical-stage therapeutic agents that specifically target this molecule. Research remains focused on understanding its regulatory networks and exploring the potential of RNA-based therapies, such as siRNA or antisense oligonucleotides, to restore or inhibit its function in therapeutic contexts [PubMed: 31213467].

Other names

Forkhead box J3FOXJ3

No drugs are currently approved or in clinical trials for this target. Experimental approaches utilize RNA interference (siRNA) or antisense oligonucleotides (ASOs) to achieve targeted degradation of FOXJ3 mRNA, thereby reducing the levels of the functional transcription factor.